Matinas BioPharma Holdings, Inc. (MTNB)

We are a clinical-stage biopharmaceutical company focused on developing
innovative anti-infectives for orphan indications. Our product and development
candidates are derived using our unique and proprietary lipid-crystal
nano-particle, or cochleate, formulation platform delivery technology. Our
proprietary cochleate delivery technology platform, licensed from Rutgers
University on an exclusive worldwide basis, nano-encapsulates drugs and is
designed to make these drugs orally bioavailable, well tolerated and safer and
less toxic while providing targeted and safe delivery of pharmaceuticals
directly to the site of infection or inflammation.  

Leave a Reply

Your email address will not be published. Required fields are marked *